Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals IncfiledCriticalAuspex Pharmaceuticals Inc
Publication of AR122596A1publicationCriticalpatent/AR122596A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
En el presente documento se proporcionan formas de dosificación osmótica que contienen deutetrabenazina para su uso en el tratamiento de, por ejemplo, trastornos del movimiento hipercinético. Cuando se administra por vía oral a un sujeto una vez al día, las formas de dosificación proporcionan un perfil farmacocinético favorable para el agente activo que indica la eficacia del tratamiento durante un período de tiempo prolongado.Osmotic dosage forms containing deutetrabenazine are provided herein for use in the treatment of, for example, hyperkinetic movement disorders. When administered orally to a subject once daily, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating efficacy of treatment over an extended period of time.
ARP210101590A2020-06-102021-06-10
OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOF
AR122596A1
(en)
Oral solid pharmaceutical dosage form of extended release comprising a matrix formulation comprising an active agent in the form of a tablet or multiparticulate; active agent is an opioid analgesic; and use in the treatment of pain. (div. sun. 499-2012).
Pharmaceutical composition covered by a film comprising capecitabine and at least one disintegrant, useful in the treatment of cancer for patients who have difficulty swallowing oral solid dosage forms.